InMed Pharmaceuticals Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scroll to see more
InMed Pharmaceuticals Inc. income statement - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingDec 2025Jun 2024Jun 2023Jun 2022Jun 2021
Revenue & Gross Profit
Revenue4.944.604.141.090.00
Cost of Revenue3.243.502.730.550.00
Gross Profit1.711.101.400.540.00
Operating Expenses
Research & Development2.853.223.737.285.34
Selling, General & Administrative6.565.805.856.874.48
Operating Expenses9.629.249.7814.349.94
Operating Income-7.92-8.13-8.38-13.79-9.94
Other Income/Expense
Interest Income0.160.530.490.100.02
Interest Expense0.370.000.000.000.00
Other Income/Expense-0.24-0.06-0.05-4.90-0.12
Income
Income Before Tax-8.16-7.67-7.93-18.60-10.20
Income Tax Expense0.000.010.010.000.00
Net Income-8.16-7.68-7.95-18.60-10.20
Net Income - Continuous Operations-8.16-7.68-7.95-18.600.00
Net Income - Discontinued Operations0.000.000.000.000.00
EBITDA-7.26-7.91-7.78-13.28-9.82
EBIT-7.92-8.13-8.38-13.79-9.94
Depreciation & Amortization0.530.220.200.190.12
Earnings Per Share
Basic EPS-11.00-20.00-65.00-663.00-759.00
Diluted EPS-11.00-20.00-65.00-663.00-759.00
Basic Shares Outstanding0.980.380.120.030.01
Diluted Shares Outstanding0.980.380.120.030.01